PMID: 3383970Apr 1, 1988Paper

Quantifying the carcinogenicity of antineoplastic drugs

European Journal of Cancer & Clinical Oncology
J M KaldorK Hemminki

Abstract

It has been well established that many of the drugs used in cancer therapy are themselves potentially carcinogenic. It is therefore important to quantify the carcinogenic risk associated with specific agents, and to investigate ways of predicting their risk from animal and in vitro studies. In this paper, an index of carcinogenic potency is defined, and applied to published data on acute non-lymphocytic leukemia following therapy with cytotoxic drugs used as single agents. Carcinogenic potency estimates for rats and mice are also obtained for 15 antineoplastic drugs, and the potency correlation between humans and rodents is examined for the five agents for which there are data in common. The broader implications for quantitative cancer risk prediction are discussed.

References

May 3, 1976·Zeitschrift Für Krebsforschung Und Klinische Onkologie. Cancer Research and Clinical Oncology·D Schmähl, M Habs
Feb 1, 1978·Cancer·N Einhorn
Oct 4, 1979·The New England Journal of Medicine·D E BergsagelA B Miller
Nov 1, 1979·Journal of Toxicology and Environmental Health·E Crouch, R Wilson
Dec 10, 1977·British Medical Journal·H StottD A Galton
Oct 1, 1977·Cancer·J C ArseneauV T DeVita
May 15, 1987·International Journal of Cancer. Journal International Du Cancer·J M KaldorF E Neal
Feb 1, 1986·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·L S GoldD Hoel
Sep 1, 1986·Annals of Internal Medicine·M H GreeneJ D Boice
Feb 1, 1985·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·L BernsteinD G Hoel
Jun 16, 1971·Nature: New Biology·H M SobellC E Nordman
Nov 3, 1983·The New England Journal of Medicine·J D BoiceJ F Fraumeni
Dec 1, 1982·British Journal of Haematology·R BuckmanD A Galton
Feb 19, 1981·The New England Journal of Medicine·P D BerkL R Wasserman

❮ Previous
Next ❯

Citations

Jan 1, 1993·Mutation Research·L R Ferguson, B C Baguley
Dec 1, 1994·Mutation Research·L F Povirk, D E Shuker
Jun 1, 1992·Risk Analysis : an Official Publication of the Society for Risk Analysis·C C Travis, J M Morris
Jun 1, 1992·Risk Analysis : an Official Publication of the Society for Risk Analysis·M J Goddard, D Krewski
Jun 1, 1992·Risk Analysis : an Official Publication of the Society for Risk Analysis·K WatanabeL Zeise
Oct 1, 1994·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·A GoughM Graziano
Sep 6, 2003·British Journal of Haematology·Gerold MeinhardtRalf Schmidmaier
Feb 22, 2013·Environmental and Molecular Mutagenesis·Souk PhonethepswathStephen D Dertinger
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L R FergusonP Morecombe
Sep 1, 1989·Japanese Journal of Cancer Research : Gann·L TomatisL Shuker
Mar 1, 1996·Baillière's Clinical Haematology·F E van Leeuwen
Sep 9, 2011·Journal of Enzyme Inhibition and Medicinal Chemistry·Beata KolesinskaMarta Switalska
Aug 28, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lindsay M MortonFlora E van Leeuwen
Aug 1, 1993·Risk Analysis : an Official Publication of the Society for Risk Analysis·D KrewskiM Szyszkowicz
Jan 1, 1994·Acta Oncologica·P Boffetta, J M Kaldor
Jan 4, 1990·The New England Journal of Medicine·J M KaldorS Karjalainen
Jan 1, 1993·Environmental and Molecular Mutagenesis·E W VogelM J Nivard
Jul 20, 2004·Chemical Research in Toxicology·Shawn BalcomeNatalia Tretyakova

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.